BiotechTube
Home/Pipeline/HBM9027

HBM9027

Pancreatic Cancer

Phase 1Active (Global)

Key Facts

Indication
Pancreatic Cancer
Phase
Phase 1
Status
Active (Global)
Company
Harbour BioMed

About Harbour BioMed

Harbour BioMed is a publicly traded biotech (HKEX: 02142) with a mission to deliver breakthrough medicines through its innovative antibody technology platforms. The company has successfully transitioned from a technology licensor to a clinical-stage entity with a maturing pipeline, evidenced by multiple out-licensing deals and strategic collaborations with major pharmaceutical companies. Its 'global for global' strategy leverages R&D centers in the US, Europe, and China to build a diversified portfolio of novel therapeutics.

View full company profile

Therapeutic Areas

ImmunologyOncologyMetabolic Diseases

Other Pancreatic Cancer Drugs

DrugCompanyPhase
Ampligen® (rintatolimod)AIM ImmunoTechEarly Access Program
Small-Molecule TherapeuticAIkido LabsPre-clinical
SIMBs + ImmunotherapyAdvanced MicrobubblesPre-clinical
CLS-014CLS TherapeuticsPre-clinical
SOMA PlatformCoherence NeuroPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Pancreatic Cancer TestMosaique DiagnosticDevelopment
Iontophoretic SystemContinuity BiosciencesPre-clinical
Lixumistat (IM156)ImmunoMet TherapeuticsPhase 1b
Electron IORTIntraop MedicalApproved
SBT-100Singh BiotechnologyPre-clinical
KRAS G12D-Targeted PCCIndi MolecularPreclinical